Abstract: The present disclosure relates more particularly to active optical fibers, amplified spontaneous emission (ASE) sources using such active optical fibers, and imaging and detection systems and methods using such ASE sources. In one aspect, the disclosure provides an active optical fiber that includes a rare earth-doped gain core configured to emit radiation at at least a peak wavelength emitted wavelength when pumped with pump radiation having a pump wavelength; a pump core surrounding the gain core; and a cladding surrounding the pump core, wherein the value M=16R2(NA)2/?2 in which R is the gain core radius, NA is the active optical fiber numerical aperture, and ? is the peak emitted wavelength, is at least 50, or at least 100. The present disclosure also provides an optical source that includes the optical fiber coupled to a pump source.

Abstract: The present invention relates to imidazotriazinone-containing compositions for nasal administration which, besides the cGMP PDE inhibitor, contain a small amount of a local anaesthetic.

Abstract: The invention relates to compositions for nasal application containing cGMP-PDE inhibitors, especially PDE5 inhibitors, also containing a small amount of local anaesthetic in addition to said cGMP PDE inhibitor.

Abstract: The present invention relates to imidazotriazinone-containing compositions for nasal administration which, besides the cGMP PDE inhibitor, contain a small amount of a local anaesthetic.

Abstract: The present invention relates to imidazotriazinone-containing compositions for nasal administration which, besides the cGMP PDE inhibitor, contain a small amount of a local anaesthetic.

Abstract: The invention relates to drug formulations which comprise 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quino-lonecarboxylic acid and/or pharmaceutically tolerable salts thereof and/or hydrates thereof as active compound which release the active compound they contain at a defined release rate.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is hydroxy-C.sub.2-8 -alkyl containing 1-5 OH-groups;R.sup.2 is hydrogen, C.sub.1-4 -alkyl or R.sup.1 ;R.sup.3 and R.sup.4 can be identical or different, and each independently is hydrogen or C.sub.1-4 -alkyl; andX is straight chain or branched C.sub.2-12 alkylene interrupted by sulfur or selenium atoms, and, optionally, additionally interrupted by oxygen atoms, by a di(C.sub.1-4 -alkyl)silyl group or a tetra(C.sub.1-4 -alkyl)disiloxane group;are very useful as X-ray contrast media opaque agents, which can be employed even in lymphography.